SAB has won an expanded scope from the US DoD on its Rapid Response contract for its new therapeutic drug candidate, SAB-185, to treat Covid-19 pandemic.

The post SAB and DoD advance therapeutic drug candidate for Covid-19 appeared first on Army Technology.